Lumicell was awarded several Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) and the National Science Foundation (NSF) that led to the initial scientific discoveries and preliminary work with our academic collaborators. These results have led to several scientific publications. The compelling data from these studies guide Lumicell’s ongoing clinical trials.
- Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system.
Smith, B.L., Gadd, M.A., Lanahan, C.R. et al. Breast Cancer Res Treat (2018) 171: 413.
- A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Science Translational Medicine 06 Jan 2016: Vol. 8, Issue 320, pp. 320ra4 DOI: 10.1126/scitranslmed.aad0293
- International Journal of Radiation Oncology, Biology, Physics
Int J Radiat Oncol Biol Phys. 2013 May 1; 86(1):136-42. doi: 10.1016/j.ijrobp.2012.12.007. Epub 2013 Feb 4.
Imaging primary mouse sarcomas after radiation therapy using cathepsin-activatable fluorescent imaging agents.
Cuneo KC, Mito JK, Javid MP, Ferrer JM, Kim Y, Lee WD, Bawendi MG, Brigman BE, Kirsch DG.
- Clinical Orthopaedics and Related Research
Clin Orthop Relat Res. 2013 Mar; 471(3):834-42. doi: 10.1007/s11999-012-2560-8.
A novel imaging system permits real-time in vivo tumor bed assessment after resection of naturally occurring sarcomas in dogs.
Eward WC, Mito JK, Eward CA, Carter JE, Ferrer JM, Kirsch DG, Brigman BE.
Cancer. 2012 Nov 1; 118(21):5320-30. doi: 10.1002/cncr.27458. Epub 2012 Mar 21.
Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging.
Mito JK, Ferrer JM, Brigman BE, Lee CL, Dodd RD, Eward WC, Marshall LF, Cuneo KC, Carter JE, Ramasunder S, Kim Y, Lee WD, Griffith LG, Bawendi MG, Kirsch DG.